medigraphic.com
ISSN 0185-3252 (Impreso)
Revista de la Asociación Médica del Centro Médico ABC

1999, Número 1

<< Anterior Siguiente >>

An Med Asoc Med Hosp ABC 1999; 44 (1)


Amiodarona intravenosa

Fabregat JR, Zacarías JL, Javier RF

Idioma: Español
Referencias bibliográficas: 37
Paginas: 36-41
Archivo PDF: 150.02 Kb.


RESUMEN

En México se utiliza ampliamente la presentación intravenosa de la amiodarona, y aunque se trata de la misma sustancia que la que se administra por vía oral, su fórmula galénica, así como los efectos de plasticidad celular que esta sustancia tiene sobre el miocardio cuando se administra crónicamente, hacen que estas dos formas de administración se comporten como si se tratara de dos antiarrítmicos diferentes con nombre igual. Se presenta una breve revisión sobre la farmacodinamia de esta sustancia, uno de los antiarrítmicos más indicados en nuestro país.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Masini E, Planchenault J, Pezziardi F, Gauthier P, Gagnol JP. Histamine releasing properties of polisorbate 80 in vitro in vivo: Correlation with its hypotensive action in the dog. Agent Actions 1985; 16: 470-477.

  2. Muñoz A, Karila P, Gallay P et al. A randomize hemodynamic comparison of intravenous amiodarone with and without solvant. Eur Heart J 1988; 9: 142-148.

  3. Nosál R, Ondrias K, Pecivova J, Drábiková K. Histamine liberation and membrane fluidisation of mast cells exposed to the beta adrenoceptor blocking drug propranolol. Agents Actions 1988, 23: 143-145.

  4. Coutte R, Fontaine G, Frank R, Dragodanne C, Phan-Thuc H, Facquet J. Studied électrocardiologique des effects de I’amiodarone sur la conduction intracardiaque chez l’homme. Ann Cardiol Angeiol 1976; 25: 543-548.

  5. Nattel S, Davies M, Quantz M. The antiarrhytmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs acute miocardial infarction. Circulation 1988; 77: 200-208.

  6. Debbas NMG, Du Cailar C, Sassine A, Derancourt J, Demaille JG, Puech P. Determination of cardiac and plasma drug levels during long term amiodarone therapy. Eur J Clin Invest 1982; 13: 123-127.

  7. Touboul P, Huerta F, Porte J, Delahaye JP. Bases électrophysiologiques de l’action antiarythmique de l’amiodarone chez l’homme. Arch Mal Coeur 1976; 69: 845-853.

  8. Cabasson J, Puech P, Mellet JM, Guimond C, Bachy C, Sassine A. Analyse des effets életrophisiologiques de l’amiodarone par l’enregistrement simultané des potentiels d’action monophasique et du faisceau de His. Arch Mal Coeur 1976; 7: 691-399.

  9. Singh BN, Vaugham-Williams EM. The effect of amiodarone, a new antianginal drug on cardiac muscle. Br J Pharmac 1970, 39: 657-667.

  10. Rougier O, Vassort G, Stämfli R. Voltage clamp experiments on frg atrial heart muscle fibres with the sucrose-gap technique. Plflügrs Arch 1968; 301: 91-108.

  11. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization induced automaticity in guinea papillary muscle by amiodarone. Circ Res 1984; 55: 277-285.

  12. Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: Evidence for calcium channel-blocking activity. Circulation 1987; 76: 442-449.

  13. Pritchard DA, Singh BN, Hurley PJ. Effects of amiodarone and thyroid function in patients with ischaemic heart disease. Br Heart J 1975; 37: 856-60.

  14. Kerin NZ, Blevins RD, Benaderet D et al. Relation o serum reverse T3 to amiodarone antiarrhytmic efficacy and toxicity. Am J Cardiol 1986; 57: 128-30.

  15. Williams LT, Lefkowitz RJ, Hathaway DR, Watanabe AM, Besch HR. Tiered Hormone regulation of beta-adrenergic receptor number. J Biol Chem 1977; 252: 2787.

  16. Sing BM. Amiodarone: Electropharmacologic Properties. In: Vaugham-Williams EM, Campbell TJ (eds). Antiarrhytmic Drugs. Handbook of experimental pharmacology. Vol 89. Berlin: Springer-Verlag, 1989; 335-364.

  17. Bigger JT, Hoffman BF. Antiarrhytmic drugs. In: Goodman-Gilman A, Goodman LS, Rall TW, Murad F (eds). The pharmacological basis of therapeutics. 7th. ed. New York: Mac Millan Publishing Company, 1985; 748-783.

  18. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation with does not produce competitive blockade of adrenoreceptors. Br J Pharmacol 1970; 39: 668.

  19. Sharma AD, Corr PB, Sobel BE. Modulation by amiodarone of cardiac adrenergic receptors in their electrophysilogic responsiveness to catecholamines (Abstr). Circulation 1983; 68 (2): 393.

  20. Vastesaeger M, Gillot P, Rasson G. Etude clinique d’une nouvelle médication antiangoreuse. Acta Cardiol 1967; 22: 483-488.

  21. Gough WB, Zeiler RH, Barreca P, El-Sherif N. Hypotensive action of commercial intravenous amiodarone and polisorbate 80 in dogs. J Cardivasc Pharmac 1982; 4: 375-380.

  22. Cote P, Bourassa MG, Delaye J, Janine A, Froment R, David P. Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease. Circulation 1979; 59: 1165-1172.

  23. Torres-Arraut E, Singh S, Pickoffas. Electrophysiologic effects of tween 80 in the myocardium and specialized conduction of the carine heart. J Electrocardiol 1984; 17: 145-151.

  24. Platou ES, Refsum H. Acute electrophysiologic and blood pressure effects of amiodarone and its solvent in dogs. Acta Pharmacol Toxicol (Copenh) 1986; 58: 163-168.

  25. Flynn SB, Gristwood RW, Owen DA. Differentiation of the roles of histamine H1 and H2 receptors in the mediation of the effects of histamine in the isolated working heart of the ginea pig. Br J Pharmacol 1979; 65: 127-137.

  26. Wollemann M, Papp JG. Blockade by cimetidine of the effects of histamine on adenylate cyclase activity, spontaneous rate and contractility in the developing prenatal heart. Agents Actions 1979; 9: 29-30.

  27. Mannaioni PF. Interaction between histamine and dichlor-isoproterenol, hexametonium, pentidine and diphenhydramine in normal and reserpine treated heart preparations. Br J Pharmacol 1960; 15: 500-505.

  28. Trendelembur U. The action of histamine and 5-hydroxytryptamine on isolated mammalian atria. J Pharmacol Exp Ther 1960; 130: 450-460.

  29. Levi R, Malm JR, Bowman FO, Rosen MR. The arrythmogenic actions of histamine on human atrial fibers. Circ Res 1981; 49: 545-550.

  30. Flacke W, Atanackovic D, Gillis RA, Alper MH. The actions of histamine on the mammalian heart. J Pharmacol Exp Ther 1967; 155: 271-278.

  31. Levi R, Kuye JO. Pharmacological characterization of cardiac histamine receptors Sensitivity to H1 receptor antagonists. Eur J Pharmacol 1974; 27: 330-338.

  32. Levi R, Kuye JO. Pharmacological characterization of cardiac histamine receptors. Sensitivity to H1 receptor antagonists. Eur J Pharmacol 1974; 27: 330-338.

  33. Wiedmeier VT, Spell LH. Effects of catecholamines, histamine and nitroglycerin on fow, oxygen utilization, and adenosine production in the perfused guinea pig heart. Circ Res 1977; 41: 503-508.

  34. Sakuma I, Genovese A, Gross SS et al. Histamine-induced atrioventricular conduction block mediated by adenosine. Circulation 78 (4 part II), 1988; 349. Abstract.

  35. Fabregat JR. Modulation de l’action electrophysiologique de l’amiodarone par sa formule galenique ou par modulation du tonus sympatique. Memoires de la Faculté de Médécine de Montpellier. France, 1989.

  36. Levine JH, Massumi A, Scheinman MM et al. Intravenous Amiodarone for recurrent sustained hypotensive ventricular tachyarrhytmias. Intravenous Amiodarone Multicenter Trial Group. J Am Cardio 1996; 27 (1): 67-75.

  37. Chow MS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996; 30 (6): 637-643.




2020     |     www.medigraphic.com